Dopamine Articles
DIET AND PARKINSONS DISEASE
21 March 1994
SOMATIX BROADENS GVAX TRIAL FOCUS
28 February 1994
DEPRENYL ACQUIRES PARKINSON'S DRUG
28 February 1994
INTERNEURON LIVING OFF THE FAT OF THE LAND
14 February 1994
ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES
31 January 1994
1993 A GRIM YEAR FOR INDUSTRY, SAYS SANOFI
6 December 1993
SCIOS NOVA FORMS CNS SUBSIDIARY
11 October 1993
NEUROSEARCH PRODUCT PIPELINE OVERVIEW
2 August 1993
TANABE AND SANDOZ IN DRUG ALLIANCE
2 August 1993
ANALYSTS SAY PROCORDIA SPLIT IS SOUND LOGIC
19 July 1993
FAVORABLE TOXICITY FOR TANAPRIL
5 July 1993
NEW DIRECTION FOR PARKINSONS?
31 May 1993
FATTY ACIDS LINKED TO SCHIZOPHRENIA?
17 May 1993
SCHIZOPHRENIA MARKET WORTH $2 BILLION BY 2002
17 May 1993
ZOFRAN STUDY RESULTS
26 April 1993
SYNTHELABO FRENCH LAUNCH
26 April 1993
FURTHER CLUES TO CLOZARIL ACTION
26 April 1993
NOVO NORDISK EXPANDING ITS FOCUS
26 April 1993
PROFITS FALL AT KYOWA HAKKO
22 March 1993
NEW MAOIs: NOT SELECTIVE ENOUGH
8 March 1993
FISONS LICENSES OUT DOPACARD
15 February 1993
ZENECA'S PROMISING R&D PIPELINE PRESENTED
14 December 1992
NEW APPROACHES IN TREATING PARKINSONISM
7 December 1992
SYNTHELABO INTENDS TO UP INTERNATIONAL STATUS
25 May 1992
FIDIA'S GM1 AND PARKINSONISM
11 May 1992
ZOFRAN APPROVED IN UK FOR PONV
11 May 1992
1991 MARKED SIGNIFICANT YEAR FOR DEPRENYL
4 May 1992
PROJECT REVIEW FROM NOVO NORDISK
27 April 1992
DEPRESSION: THE COST TO SOCIETY
6 April 1992
DEPRESSION: THE COST TO SOCIETY
6 April 1992
FOCUS ON JANSSEN'S RISPERDOL
16 March 1992
PRODUCT UPDATE FROM INTERNEURON PHARMA
9 March 1992
ROBERTS PURCHASES RIGHTS TO DOPAR
6 January 1992
- Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- It's official: "obesity is a disease," says AMA
- Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD
